Christina Papini, Irfan Ullah, Amalendu P Ranjan, Shuo Zhang, Qihao Wu, Krasimir A Spasov, Chunhui Zhang, Walther Mothes, Jason M Crawford, Brett D Lindenbach, Pradeep D Uchil, Priti Kumar, William L Jorgensen, Karen S Anderson
As the SARS-CoV-2 virus continues to spread and mutate, it remains important to focus not only on preventing spread through vaccination but also on treating infection with direct-acting antivirals (DAA). The approval of Paxlovid, a SARS-CoV-2 main protease (Mpro ) DAA, has been significant for treatment of patients. A limitation of this DAA, however, is that the antiviral component, nirmatrelvir, is rapidly metabolized and requires inclusion of a CYP450 3A4 metabolic inhibitor, ritonavir, to boost levels of the active drug...
April 23, 2024: Proceedings of the National Academy of Sciences of the United States of America